Inflation rebates to reduce Medicare payment for 27 Part B drugs
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere between 10% and 19.9%, depending on the drug, the Centers for Medicare & Medicaid Services announced today.
The IRA requires drug companies to pay rebates to Medicare when prices for certain single-source and biosimilar prescription drugs covered under Part B increase faster than the rate of inflation. These 27 drugs are among the first rebatable drugs under the law. Part B drugs impacted by a coinsurance adjustment may change quarterly. For more information, see the CMS fact sheet.
Related News Articles
Headline
The White House announced today that it reached agreements with Eli Lilly and Novo Nordisk to align their drug prices with the lowest paid by other developed…
Headline
The AHA has released a social media toolkit with sample posts and graphics encouraging people to sign up for 2026 health coverage via the Health Insurance…
Headline
Cigna’s Evernorth division Oct. 27 announced a new, rebate-free pharmacy benefit model, beginning in 2027, that would reduce monthly prescription drug costs by…
Headline
A new report from KFF reveals that Medicare Advantage enrollees had access to just 48% of the physicians available to Traditional Medicare beneficiaries in…
Headline
The median net launch price for 154 new drugs increased 51% between 2022 and 2024, after accounting for inflation and discounts, according to a report released…
Headline
The AHA Oct. 23 recommended changes to the Centers for Medicare & Medicaid Services’ Wasteful and Inappropriate Services Reduction model to address…